论文部分内容阅读
目的探讨阿奇霉素在小儿肺炎支原体肺炎(MPP)治疗中的应用价值。方法选择我院儿科2016年2月-2017年2月诊治的78例小儿MPP病例进行临床试验,并按随机非盲法分组(39例/组),Ⅰ组接受红霉素静滴,用量20-30mg/kg·d-1,Ⅱ组连续3-5d接受阿奇霉素10mg/kg·d-1静滴,再取本品口服,1个疗程后,观察两组的药物应用情况。结果经相应药物方案治疗后,Ⅱ组的临床总有效率(97.4%)显著提高,与Ⅰ组(82.1%)相比差异显著(P<0.05)。在咳嗽、发热等肺炎症状方面,Ⅱ组平均消失时间显著缩短,住院时间显著缩短,与Ⅰ组相比差异显著(P<0.05)。结论阿奇霉素对小儿MPP的治疗具有显著的药效,能够促进相关肺炎症状的恢复,缩短患儿的住院时间,值得加强推广。
Objective To investigate the value of azithromycin in the treatment of children with Mycoplasma pneumoniae pneumonia (MPP). Methods A total of 78 children with MPP who were diagnosed and treated in our hospital from February 2016 to February 2017 were enrolled in this study. Randomized non-blinded group (39 cases / group) received intravenous infusion of erythromycin -30mg / kg · d-1. Group Ⅱ received intravenous infusion of azithromycin 10mg / kg · d-1 for 3-5 consecutive days. Oral administration of this product was given orally. After 1 course of treatment, the drug application was observed in both groups. Results The total effective rate of group Ⅱ (97.4%) was significantly higher than that of group Ⅰ (82.1%) (P <0.05). In the cough, fever and other symptoms of pneumonia, the average disappearance time of group Ⅱ was significantly shorter, hospitalization time was significantly shortened, compared with the group Ⅰ significant difference (P <0.05). Conclusion Azithromycin has a significant effect on the treatment of pediatric MPP, which can promote the recovery of related pneumonia symptoms and shorten the hospitalization time of children, which is worth to be promoted.